A phase 2 randomized, parallel-arm study of oral direct factor Xa-inhibitor apixaban and low molecular weight heparin or fondaparinux with a vitamin K antagonist in subjects with acute symptomatic deep vein thrombosis.
Active, not recruiting
- Conditions
- Treatment of subjects with acute syntomatic deep vein thrombosis.MedDRA version: 9.1Level: HLTClassification code 10034572Term: Peripheral embolism and thrombosis
- Registration Number
- EUCTR2005-001388-71-IT
- Lead Sponsor
- BRISTOL-M.SQUIBB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 660
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method